Patients with evidence of distant metastases or leptomeningeal disease (LMD) are excludedXx_NEWLINE_xXHistory of leptomeningeal diseaseXx_NEWLINE_xXSymptomatic or untreated leptomeningeal or brain metastases or spinal cord compressionXx_NEWLINE_xXSymptomatic brain metastasis or leptomeningeal diseaseXx_NEWLINE_xXAssociated with either diffuse subependymal or leptomeningeal dissemination; orXx_NEWLINE_xXHistory of brain involvement with cancer, spinal cord compression, or carcinomatous meningitis, or new evidence of brain or leptomeningeal disease. Patients with radiated or resected lesions are permitted, provided the lesions are fully treated and inactive, patients are asymptomatic, and no steroids have been administered for at least 28 days prior to randomizationXx_NEWLINE_xXPatient must not have leptomeningeal diseaseXx_NEWLINE_xXLeptomeningeal diseaseXx_NEWLINE_xXHistory of brain involvement with cancer, spinal cord compression, or carcinomatous meningitis, or new evidence of brain or leptomeningeal disease.Xx_NEWLINE_xXLeptomeningeal diseaseXx_NEWLINE_xXLeptomeningeal disease as the only manifestation of the current malignancyXx_NEWLINE_xXMultifocal disease or leptomeningeal disease (LM) disease on post-operative MRI;Xx_NEWLINE_xXUntreated CNS metastatic disease, leptomeningeal disease, or cord compressionXx_NEWLINE_xXUntreated or symptomatic brain metastases and leptomeningeal diseaseXx_NEWLINE_xXSymptomatic or untreated leptomeningeal disease or spinal cord compressionXx_NEWLINE_xXLeptomeningeal metastasesXx_NEWLINE_xXHistory of leptomeningeal disease;Xx_NEWLINE_xXHistory of leptomeningeal metastatic diseaseXx_NEWLINE_xXLeptomeningeal diseaseXx_NEWLINE_xXPatients with brain metastases (treated or untreated) leptomeningeal disease, uncontrolled seizure disorder, or active neurologic diseaseXx_NEWLINE_xXSymptomatic or uncontrolled brain metastases requiring concurrent treatments, uncontrolled spinal cord compression, carcinomatous meningitis, or new evidence of brain or leptomeningeal disease; uncontrolled seizures.Xx_NEWLINE_xXLeptomeningeal involvement of cancerXx_NEWLINE_xXPatients with uncontrolled brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastasesXx_NEWLINE_xXLeptomeningeal diseaseXx_NEWLINE_xXPatients with leptomeningeal disease are not eligible for participation\r\n* Please note: leptomeningeal enhancement is not an exclusionXx_NEWLINE_xXLeptomeningeal diseaseXx_NEWLINE_xXLeptomeningeal metastasesXx_NEWLINE_xXKnown leptomeningeal diseaseXx_NEWLINE_xXCytologic or unequivocal radiographic confirmation of leptomeningeal metastasis by dural puncture and/or neuroimaging with or without known brain metastasisXx_NEWLINE_xXKnown leptomeningeal carcinomatosis, uncontrolled/unstable spinal cord compression, or brain metastases.Xx_NEWLINE_xXNo history or evidence by CT scan or MRI, of brain metastases or leptomeningeal disease.Xx_NEWLINE_xXHistory of leptomeningeal disease or spinal cord compression secondary to metastasisXx_NEWLINE_xXLeptomeningeal disease as the only site of CNS involvementXx_NEWLINE_xXPositive cerebrospinal fluid (CSF) cytology during staging, symptomatic leptomeningeal involvement, or parenchymal involvement of brain or spinal cordXx_NEWLINE_xXKnown or suspected brain metastasis or active leptomeningeal diseaseXx_NEWLINE_xXUncontrolled brain or leptomeningeal metastases from plexiform neurofibromas, malignant peripheral nerve sheath tumors, or other cancers (other than proven or probable low grade astrocytomas), including patients who continue to require glucocorticoids for control of symptoms related to brain or leptomeningeal metastasesXx_NEWLINE_xXKnown leptomeningeal or brainstem metastases. The presence of leptomeningeal enhancement alone, without associated clinical manifestations and/or positive CSF cytology, will not be constituted as known leptomeningeal metastasesXx_NEWLINE_xXKnown leptomeningeal or brainstem metastases (defined as positive CSF cytology and/or unequivocal radiological evidence of clinically significant leptomeningeal involvement; CSF sampling is not required in the absence of suggestive symptoms to exclude leptomeningeal involvement)Xx_NEWLINE_xXParticipants with widespread, definitive leptomeningeal diseaseXx_NEWLINE_xXOr any history of leptomeningeal metastasis.Xx_NEWLINE_xXHave symptomatic or uncontrolled brain metastases, spinal cord compression, or leptomeningeal disease requiring concurrent treatment, including but not limited to surgery, radiation, and/or corticosteroids (participants receiving anticonvulsants are eligible).Xx_NEWLINE_xXParticipants with widespread, definitive leptomeningeal diseaseXx_NEWLINE_xXLeptomeningeal metastasesXx_NEWLINE_xXAny known brain or leptomeningeal metastases are excluded, even if treated.Xx_NEWLINE_xXHas a history of untreated brain metastasis or history of leptomeningeal disease or spinal cord compressionXx_NEWLINE_xXPresence of brain metastasis or leptomeningeal spread of the diseaseXx_NEWLINE_xXPresence of gliomatosis cerebri, cranial or spinal leptomeningeal metastatic diseaseXx_NEWLINE_xXMetastases detected below the tentorium or beyond the cranial vault, including tumors with evidence of leptomeningeal metastases as previously indicated;Xx_NEWLINE_xXHave symptomatic brain metastases or leptomeningeal diseaseXx_NEWLINE_xXHistory of leptomeningeal carcinomatosisXx_NEWLINE_xXKnown brain metastases or leptomeningeal disease involvement. Glioblastoma lesions (primary or locally advanced) are eligible.Xx_NEWLINE_xXPresence of gliomatosis cerebri, cranial or spinal leptomeningeal metastatic diseaseXx_NEWLINE_xXLeptomeningeal diseaseXx_NEWLINE_xXPatients must be diagnosed with leptomeningeal carcinomatosis.Xx_NEWLINE_xXPresence of leptomeningeal metastasesXx_NEWLINE_xXBrain metastasis and/or leptomeningeal disease (known or suspected)Xx_NEWLINE_xXPatients with leptomeningeal diseaseXx_NEWLINE_xXHistory of leptomeningeal carcinomatosisXx_NEWLINE_xXHistory of leptomeningeal carcinomatosis.Xx_NEWLINE_xXPatients with leptomeningeal metastasis.Xx_NEWLINE_xXPatients with a history of brain/leptomeningeal metastasisXx_NEWLINE_xXDiffuse Leptomeningeal metastases with radiographic involvement in the brain and/or spinal cord. This does not include local leptomeningeal involvement which is defined as leptomeningeal enhancement within direct contact of targetable metastasesXx_NEWLINE_xXLeptomeningeal disease or uncontrolled brain metastasisXx_NEWLINE_xXPresence of extracranial metastatic, significant leptomeningeal disease or tumors primarily localized to the brainstem or spinal cord.Xx_NEWLINE_xXLeptomeningeal diseaseXx_NEWLINE_xXKnown brain or leptomeningeal metastasesXx_NEWLINE_xXHas evidence of leptomeningeal diseaseXx_NEWLINE_xXNo concurrent leptomeningeal disease or cord compressionXx_NEWLINE_xXPatients with leptomeningeal metastases documented by MRI or cerebrospinal fluid (CSF) evaluationXx_NEWLINE_xXSubject has known symptomatic brain metastases or leptomeningeal involvement as assessed by CT scan or MRI. Subjects with stable asymptomatic brain metastases or leptomeningeal disease are eligible provided that they have not required new treatments for this disease in a 28 day period before the first dose of study drug, and anticonvulsants and steroids have not been administered for a period of 2 weeks prior to the first dose of study drug.Xx_NEWLINE_xXPatient has leptomeningeal diseaseXx_NEWLINE_xXLesions on imaging, by cerebrospinal fluid or with neurological findings that are consistent with leptomeningeal disease or meningeal carcinomatosis.Xx_NEWLINE_xXKnown symptomatic uncontrolled brain or leptomeningeal metastases (Day 1)Xx_NEWLINE_xXHistory of leptomeningeal carcinomatosisXx_NEWLINE_xXHistory of leptomeningeal diseaseXx_NEWLINE_xXDiffuse leptomeningeal gliomatosisXx_NEWLINE_xXPatients with leptomeningeal disease (leptomeningeal enhancement on MRI/CT imaging and/or positive cerebrospinal fluid [CSF] cytology) are not eligible to enrollXx_NEWLINE_xXHistory of leptomeningeal diseaseXx_NEWLINE_xXHas evidence of leptomeningeal disease on MRI or in cerebrospinal fluid (CSF)Xx_NEWLINE_xXKnown or suspected brain metastasis or active leptomeningeal diseaseXx_NEWLINE_xXUntreated CNS or leptomeningeal metastasis\r\n* Note: CNS or leptomeningeal disease must be stable for >= 3 months prior to registrationXx_NEWLINE_xXHistory of leptomeningeal carcinomatosisXx_NEWLINE_xXUncontrolled brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastases.Xx_NEWLINE_xXHistory of leptomeningeal carcinomatosisXx_NEWLINE_xXUncontrolled metastases to the central nervous system (CNS) or cytological/radiographic evidence of leptomeningeal carcinomatosis. Participants with brain metastases (other than leptomeningeal carcinomatosis) are eligible provided they do not require ongoing steroids and have shown clinical and radiographic stability for at least 28 days after definitive therapy. Primary glioblastoma is allowed.Xx_NEWLINE_xXSubjects with leptomeningeal metastases in lumbar area.Xx_NEWLINE_xXHistory of leptomeningeal metastasesXx_NEWLINE_xXSymptomatic brain metastases, leptomeningeal carcinomatosis, or spinal cord compression (treated metastatic brain, leptomeningeal carcinomatosis, or spinal cord compression are allowed); Note: Patients must be off steroids used for brain metastases, leptomeningeal carcinomatosis, or spinal cord compressionXx_NEWLINE_xXHistory of leptomeningeal carcinomatosisXx_NEWLINE_xXHistory of leptomeningeal carcinomatosis.Xx_NEWLINE_xXPatients with asymptomatic leptomeningeal disease are eligible for participation in this trial; however, patients who had progression of leptomeningeal disease on alectinib will be required to undergo CNS radiation to meet eligibilityXx_NEWLINE_xXHistory of leptomeningeal carcinomatosisXx_NEWLINE_xXPatients with known leptomeningeal metastatic diseaseXx_NEWLINE_xXHistory of brain involvement with cancer, spinal cord compression, or carcinomatous meningitis, or new evidence of brain or leptomeningeal disease (Note: Patients with radiated or resected lesions are permitted, provided the lesions are fully treated and inactive, patients are asymptomatic, and no steroids have been administered over the 14 days prior to study treatment)Xx_NEWLINE_xXPatients with leptomeningeal diseaseXx_NEWLINE_xXLeptomeningeal diseaseXx_NEWLINE_xXSymptomatic or untreated leptomeningeal diseaseXx_NEWLINE_xXKnown or suspected brain metastasis or active leptomeningeal disease.Xx_NEWLINE_xXHistory of leptomeningeal carcinomatosisXx_NEWLINE_xXLeptomeningeal diseaseXx_NEWLINE_xXHistory of leptomeningeal carcinomatosisXx_NEWLINE_xXHistory of leptomeningeal carcinomatosisXx_NEWLINE_xXLeptomeningeal carcinomatosis or cord compressionXx_NEWLINE_xXSymptomatic or untreated brain metastases, leptomeningeal disease, or spinal cord compressionXx_NEWLINE_xXHistory of leptomeningeal carcinomatosis or brain metastasis.Xx_NEWLINE_xXIn the dose-finding portion of the study, participants with known or suspected parenchymal brain, spinal cord, leptomeningeal disease prior to study enrollment will be excluded; in the dose-expansion portion of the study, known or suspected parenchymal brain or spinal cord disease, and/or suspected or symptomatic leptomeningeal disease prior to study enrollment will be excluded; asymptomatic leptomeningeal disease only will be allowed in the dose-expansion cohortXx_NEWLINE_xXHas presence of diffuse leptomeningeal disease or extracranial diseaseXx_NEWLINE_xXHistory of leptomeningeal carcinomatosisXx_NEWLINE_xXUncontrolled brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastasesXx_NEWLINE_xXHistory of leptomeningeal carcinomatosisXx_NEWLINE_xXPatients with neoplastic lesions in the brainstem, cerebellum, or spinal cord, radiological evidence of active (growing) multifocal disease, subependymal or leptomeningeal diseaseXx_NEWLINE_xXLeptomeningeal carcinomatosis, diagnosed on cytology or appropriate imagingXx_NEWLINE_xXCurrent or previously treated brain or leptomeningeal metastasesXx_NEWLINE_xXLeptomeningeal involvement regardless of treatment statusXx_NEWLINE_xXCurrent or previously treated brain or leptomeningeal metastasesXx_NEWLINE_xXHistory of leptomeningeal carcinomatosisXx_NEWLINE_xXLeptomeningeal involvement regardless of treatment statusXx_NEWLINE_xXSymptomatic or untreated leptomeningeal or brain metastases or spinal cord compression; if these were treated and clinically stable for 4 weeks, patient can be considered for the trialXx_NEWLINE_xXActive leptomeningeal metastasesXx_NEWLINE_xXLeptomeningeal diseaseXx_NEWLINE_xXEvidence of leptomeningeal diseaseXx_NEWLINE_xXHistory of leptomeningeal carcinomatosisXx_NEWLINE_xXRadiographic or cytologic evidence of leptomeningeal or multifocal disease at any time prior to study entryXx_NEWLINE_xXSubjects with leptomeningeal disease are excludedXx_NEWLINE_xXKnown brain metastasis or leptomeningeal involvementXx_NEWLINE_xXPresence of leptomeningeal diseaseXx_NEWLINE_xXHistory of leptomeningeal carcinomatosisXx_NEWLINE_xXHave symptomatic or uncontrolled brain metastases, spinal cord compression, or leptomeningeal disease requiring concurrent treatment.Xx_NEWLINE_xXIn patients with suspected leptomeningeal disease, the diagnosis of leptomeningeal disease should be confirmed by the presence of neurological or imaging signs and/or positive cerebrospinal fluid (CSF) cytologyXx_NEWLINE_xXClinical evidence of symptomatic progressive brain or leptomeningeal disease during the past 6 monthsXx_NEWLINE_xXPatients with leptomeningeal metastasesXx_NEWLINE_xXDiagnosis of leptomeningeal diseaseXx_NEWLINE_xXHistory of leptomeningeal carcinomatosisXx_NEWLINE_xXEvidence of leptomeningeal spread of diseaseXx_NEWLINE_xXHas symptomatic or untreated leptomeningeal, brain metastases, or spinal cord compression.Xx_NEWLINE_xXHistory of leptomeningeal carcinomatosisXx_NEWLINE_xXPatients with known or suspected brain metastasis or active leptomeningeal diseaseXx_NEWLINE_xXPresence of leptomeningeal diseaseXx_NEWLINE_xXPatients with evidence of tumor in the brainstem, cerebellum, or spinal cord, or with evidence of leptomeningeal diseaseXx_NEWLINE_xXSpinal cord compression (unless treated with the patient attaining good pain control and stable or recovered neurologic function), carcinomatous meningitis, or leptomeningeal diseaseXx_NEWLINE_xXPresence of extracranial metastatic or leptomeningeal diseaseXx_NEWLINE_xXPatients with leptomeningeal metastasisXx_NEWLINE_xXLeptomeningeal metastasisXx_NEWLINE_xXHistory of leptomeningeal carcinomatosisXx_NEWLINE_xXSymptomatic or untreated leptomeningeal or brain metastases or spinal cord compressionXx_NEWLINE_xXKnown or suspected leptomeningeal disease; patients with metastases to the brain stem, midbrain, pons or medullaXx_NEWLINE_xXLeptomeningeal metastasesXx_NEWLINE_xXHistory of brain involvement with cancer, spinal cord compression, or carcinomatous meningitis, or new evidence of brain or leptomeningeal disease; patients with radiated or resected lesions are permitted, provided the lesions are fully treated and inactive, patients are asymptomatic, and no steroids have been administered for at least 28 daysXx_NEWLINE_xXLeptomeningeal diseaseXx_NEWLINE_xXRadiographic or cytologic evidence of leptomeningeal diseaseXx_NEWLINE_xXLeptomeningeal diseaseXx_NEWLINE_xXSymptomatic or untreated leptomeningeal or brain metastases or spinal cord compressionXx_NEWLINE_xXSymptomatic or untreated leptomeningeal or brain metastases or spinal cord compressionXx_NEWLINE_xXPresence of leptomeningeal diseaseXx_NEWLINE_xXMust not have leptomeningeal metastases.Xx_NEWLINE_xXInfratentorial, leptomeningeal, or multifocal tumorXx_NEWLINE_xXPresence of diffuse leptomeningeal diseaseXx_NEWLINE_xXImaging or cytologic evidence of leptomeningeal diseaseXx_NEWLINE_xXLeptomeningeal metastasesXx_NEWLINE_xXPatients will be excluded if there is radiographic or cerebrospinal fluid (CSF) cytological evidence of leptomeningeal diseaseXx_NEWLINE_xXPatients with multifocal disease or leptomeningeal disease who require whole brain radiotherapy (WBRT)Xx_NEWLINE_xXEvidence of distant metastases or distant leptomeningeal metastases at the time of diagnosisXx_NEWLINE_xXPresence of leptomeningeal diseaseXx_NEWLINE_xXHave symptomatic leptomeningeal carcinomatosis or spinal cord compression. Patients with asymptomatic leptomeningeal disease and no evidence of spinal cord compression are allowed.Xx_NEWLINE_xXDocumented and/or symptomatic or known brain or leptomeningeal metastasesXx_NEWLINE_xXSymptomatic or untreated leptomeningeal disease, brain metastasis, or spinal cord compressionXx_NEWLINE_xXFor Parts A, B, C, D, E: Have evidence of leptomeningeal metastases. Note: discrete dural metastases are permitted.Xx_NEWLINE_xXUncontrolled brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastasesXx_NEWLINE_xXUncontrolled brain or leptomeningeal metastases, including those who continue to require glucocorticoids for brain or leptomeningeal metastasesXx_NEWLINE_xXPatients must have central nervous system (CNS)/ leptomeningeal disease which is refractory to conventional therapies or for which no conventional therapy exists OR recurrent brain tumors with a predilection for leptomeningeal dissemination (primitive neuroectodermal tumor [PNET], rhabdoid tumor)Xx_NEWLINE_xXActive brain or leptomeningeal metastasis.Xx_NEWLINE_xXKnown leptomeningeal involvement.Xx_NEWLINE_xXHistory of brain metastases, uncontrolled spinal cord compression, carcinomatous meningitis, or new evidence of brain or leptomeningeal disease.Xx_NEWLINE_xXKnown or suspected brain metastasis or active leptomeningeal disease or spinal cord compressionXx_NEWLINE_xXLeptomeningeal diseaseXx_NEWLINE_xXGlioblastoma or gliosarcoma disease with leptomeningeal spread.Xx_NEWLINE_xXPatients are excluded if there is radiographic or cerebrospinal fluid (CSF) evidence of leptomeningeal disease.Xx_NEWLINE_xXHistory or presence of brain metastasis or leptomeningeal diseaseXx_NEWLINE_xXClinical signs of brain involvement or leptomeningeal diseaseXx_NEWLINE_xXPatients who have leptomeningeal diseaseXx_NEWLINE_xXSymptomatic and uncontrolled metastasis in the central nervous system or leptomeningeal or lymphangitic carcinomatosisXx_NEWLINE_xXLeptomeningeal carcinomatosisXx_NEWLINE_xXEvidence of leptomeningeal metastasesXx_NEWLINE_xXKnown or suspected brain metastasis or active leptomeningeal diseaseXx_NEWLINE_xXPatients with leptomeningeal diseaseXx_NEWLINE_xXHistory of leptomeningeal carcinomatosisXx_NEWLINE_xXHistory of leptomeningeal carcinomatosis or uncontrolled seizuresXx_NEWLINE_xXSymptomatic or untreated leptomeningeal or brain metastases or spinal cord compressionXx_NEWLINE_xXHistory of leptomeningeal carcinomatosis or brain metastasisXx_NEWLINE_xXParticipant has known leptomeningeal metastases.Xx_NEWLINE_xXKnown or suspected brain metastasis or active leptomeningeal diseaseXx_NEWLINE_xXSymptomatic or untreated leptomeningeal disease.Xx_NEWLINE_xXHistory of leptomeningeal diseaseXx_NEWLINE_xXLeptomeningeal metastasisXx_NEWLINE_xXHistory of leptomeningeal carcinomatosisXx_NEWLINE_xXHas infratentorial, or leptomeningeal evidence of recurrent diseaseXx_NEWLINE_xXLeptomeningeal diseaseXx_NEWLINE_xXEvidence of leptomeningeal disseminationXx_NEWLINE_xXUntreated brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastasesXx_NEWLINE_xXKnown leptomeningeal disease or CNS midline shiftsXx_NEWLINE_xXUntreated brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastasesXx_NEWLINE_xXEvidence of leptomeningeal metastasesXx_NEWLINE_xXSymptomatic or untreated leptomeningeal or brain metastases or spinal cord compressionXx_NEWLINE_xXPatients with symptomatic or untreated leptomeningeal or brain metastasis or spinal cord compressionXx_NEWLINE_xXLeptomeningeal carcinomatosis as only site of CNS diseaseXx_NEWLINE_xXPatient must not have known symptomatic leptomeningeal or brain metastases or spinal cord compressionXx_NEWLINE_xXPatients with symptomatic brain metastases who have not completed radiation therapy and/or are receiving systemic steroid therapy; patients with leptomeningeal disease will be excludedXx_NEWLINE_xXPatients with documented evidence of leptomeningeal diseaseXx_NEWLINE_xXHistory of known leptomeningeal involvement (lumbar puncture not required)Xx_NEWLINE_xXBrain metastases or active leptomeningeal disease (with the exception of participants with treated epidural disease and no other epidural progression)Xx_NEWLINE_xXThe participant has documented brain metastases or leptomeningeal disease.Xx_NEWLINE_xXConfirmed brain and/or leptomeningeal metastasesXx_NEWLINE_xXFor Cohort C:Has known or suspected brain metastasis or leptomeningeal carcinomatosisXx_NEWLINE_xXActive CNS metastases or leptomeningeal disease.Xx_NEWLINE_xXSubjects with leptomeningeal carcinomatosis are not permittedXx_NEWLINE_xXLeptomeningeal diseaseXx_NEWLINE_xXPatients must not have symptomatic uncontrolled brain or leptomeningeal metastases.Xx_NEWLINE_xXLeptomeningeal disease.Xx_NEWLINE_xXHave known untreated brain metastases, uncontrolled spinal cord compression, or leptomeningeal disease.Xx_NEWLINE_xXLeptomeningeal diseaseXx_NEWLINE_xXKnown or suspected brain metastasis or active leptomeningeal disease;Xx_NEWLINE_xXLeptomeningeal diseaseXx_NEWLINE_xXHistory of leptomeningeal diseaseXx_NEWLINE_xXPatients with known leptomeningeal or brain metastases or spinal cord compression should be excluded from this clinical trialXx_NEWLINE_xXHistory of brain involvement with cancer, spinal cord compression, or carcinomatous meningitis, or new evidence of brain or leptomeningeal disease. Patients with radiated or resected lesions are permitted, provided the lesions are fully treated and inactive, patients are asymptomatic, and no steroids have been administered for at least 28 days.Xx_NEWLINE_xXKnown brain metastasis or leptomeningeal diseaseXx_NEWLINE_xXHistory of leptomeningeal diseaseXx_NEWLINE_xXHistory of or known active seizure disorder, brain metastases, spinal cord compression, or carcinomatous meningitis, or new evidence of brain or leptomeningeal disease.Xx_NEWLINE_xXLeptomeningeal diseaseXx_NEWLINE_xXSubject has known or suspected brain metastasis or active leptomeningeal disease.Xx_NEWLINE_xXKnown or suspected brain metastasis or active leptomeningeal disease;Xx_NEWLINE_xXPatients must not have clinical evidence of leptomeningeal disease (a spinal tap does not need to be performed)Xx_NEWLINE_xXHave current spinal cord compression (symptomatic or asymptomatic and detected by radiographic imaging). Patients with leptomeningeal disease and without cord compression are allowed.Xx_NEWLINE_xXHistory of brain involvement with cancer, spinal cord compression, or carcinomatous meningitis, or new evidence of brain or leptomeningeal disease. Patients with radiated or resected lesions are permitted, provided the lesions are fully treated and inactive, patients are asymptomatic, and no steroids have been administered for at least 28 days.Xx_NEWLINE_xXKnown brain metastasis or leptomeningeal diseaseXx_NEWLINE_xXLeptomeningeal diseaseXx_NEWLINE_xXhave previously documented brain metastases, leptomeningeal disease, or uncontrolled spinal cord compressionXx_NEWLINE_xXHas documented brain metastases, leptomeningeal disease, or uncontrolled spinal cord compression.Xx_NEWLINE_xXDiagnosis of leptomeningeal carcinomatosisXx_NEWLINE_xXHave documented brain metastases, leptomeningeal disease or uncontrolled spinal cord compression.Xx_NEWLINE_xXHas infratentorial, or leptomeningeal evidence of recurrent diseaseXx_NEWLINE_xXHave visceral crisis, lymphangitic spread, or leptomeningeal carcinomatosisXx_NEWLINE_xXPatients with known or suspected leptomeningeal metastases.Xx_NEWLINE_xXBrain metastases, spinal cord compression, carcinomatous meningitis, or leptomeningeal disease.Xx_NEWLINE_xXPrior brain or leptomeningeal metastases allowed if asymptomatic (e.g., diagnosed incidentally at study baseline)Xx_NEWLINE_xXSubject has known or suspected primary brain or leptomeningeal metastasesXx_NEWLINE_xXParticipant has brain metastases, uncontrolled spinal cord compression, or carcinomatous meningitis, or new evidence of brain or leptomeningeal diseaseXx_NEWLINE_xXUnstable or untreated brain/leptomeningeal metastasisXx_NEWLINE_xXSymptomatic or untreated leptomeningeal or brain metastases or spinal cord compression.Xx_NEWLINE_xXSubject has known symptomatic brain metastases or leptomeningeal involvement as assessed by CT scan or MRI. Subjects with stable asymptomatic brain metastases or leptomeningeal disease are eligible if they have not required new treatments for this disease in a 28 day period before the first dose of study drug, and anticonvulsants and steroids have not been administered for a period of 2 weeks prior to the first dose of study drug.Xx_NEWLINE_xXLeptomeningeal diseaseXx_NEWLINE_xXBrain metastases or history of leptomeningeal carcinomatosisXx_NEWLINE_xXSymptomatic metastatic brain or leptomeningeal tumors (asymptomatic or treated metastatic brain or leptomeningeal tumors are allowed)Xx_NEWLINE_xXHistory of leptomeningeal carcinomatosisXx_NEWLINE_xXKnown leptomeningeal metastases not amenable to radiotherapy; patients receiving radiotherapy for leptomeningeal metastases are eligibleXx_NEWLINE_xXHistory of leptomeningeal carcinomatosisXx_NEWLINE_xXSubject has known or suspected brain metastasis or active leptomeningeal disease.Xx_NEWLINE_xXBrain metastases, leptomeningeal disease or bone metastasesXx_NEWLINE_xXSpinal cord compression, leptomeningeal carcinomatosis or active symptomatic brain metastasesXx_NEWLINE_xXThe participant has documented brain metastases, leptomeningeal disease, or uncontrolled spinal cord compression.Xx_NEWLINE_xXKnown leptomeningeal metastasesXx_NEWLINE_xXCurrent or previously treated brain metastasis or active leptomeningeal disease;Xx_NEWLINE_xXPatients with evidence of tumor in the brainstem, cerebellum, or spinal cord, radiological evidence of multifocal disease, or leptomeningeal diseaseXx_NEWLINE_xXHas presence of diffuse leptomeningeal disease or extracranial diseaseXx_NEWLINE_xXPatients with history of brain metastases, spinal cord compression, or a history of leptomeningeal carcinomatosis;Xx_NEWLINE_xXLeptomeningeal diseaseXx_NEWLINE_xXBrain metastases or leptomeningeal diseaseXx_NEWLINE_xXUnstable CNS metastases or leptomeningeal carcinomatosis not considered radiographically stableXx_NEWLINE_xXPatients with history of brain metastases, spinal cord compression, or leptomeningeal carcinomatosisXx_NEWLINE_xXUntreated brain metastasis or history of leptomeningeal disease or spinal cord compression.Xx_NEWLINE_xXSymptomatic or untreated leptomeningeal or brain metastases or spinal cord compressionXx_NEWLINE_xXCurrent leptomeningeal metastases or spinal cord compression due to disease.Xx_NEWLINE_xXKnown leptomeningeal diseaseXx_NEWLINE_xXLeptomeningeal diseaseXx_NEWLINE_xXKnown or suspected brain metastasis or active leptomeningeal diseaseXx_NEWLINE_xXPresence of extracranial metastatic or leptomeningeal diseaseXx_NEWLINE_xXUncontrolled brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastasesXx_NEWLINE_xXHistory of brain metastasis, active leptomeningeal disease or seizureXx_NEWLINE_xXLeptomeningeal diseaseXx_NEWLINE_xXPatients with leptomeningeal disease are excludedXx_NEWLINE_xXpresence of Alzheimer's disease, meningioma, leptomeningeal disease from prostate cancer.Xx_NEWLINE_xXExpansion A:\r\n* Brain metastases or leptomeningeal not previously treated with radiation or surgeryXx_NEWLINE_xXMetastatic brain or leptomeningeal tumors (treated metastatic brain or leptomeningeal tumors are allowed)Xx_NEWLINE_xXHistory of leptomeningeal diseaseXx_NEWLINE_xXLeptomeningeal carcinomatosis as the only site of CNS involvementXx_NEWLINE_xXHistory of leptomeningeal metastasesXx_NEWLINE_xXPatients with leptomeningeal disease are not eligible for participationXx_NEWLINE_xXPatients with leptomeningeal diseaseXx_NEWLINE_xXPatients with a history of brain/leptomeningeal metastasisXx_NEWLINE_xXUncontrolled brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastasesXx_NEWLINE_xXInfratentorial, or leptomeningeal evidence of recurrent diseaseXx_NEWLINE_xXActive brain metastasis or leptomeningeal metastasisXx_NEWLINE_xXSymptomatic or untreated leptomeningeal diseaseXx_NEWLINE_xXPresence of gliomatosis cerebri, cranial or spinal leptomeningeal metastatic diseaseXx_NEWLINE_xXUncontrolled brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastasesXx_NEWLINE_xXPatients with leptomeningeal diseaseXx_NEWLINE_xXSymptomatic or untreated leptomeningeal, CNS or brain metastases or spinal cord compression at the time of transition to this study.Xx_NEWLINE_xXA history of or evidence of brain metastases or leptomeningeal disease.Xx_NEWLINE_xXThose with leptomeningeal metastases as the only site of CNS diseaseXx_NEWLINE_xXPatients with neoplastic lesions in the brainstem, cerebellum or spinal cord, radiological evidence of active (growing) multifocal disease, or leptomeningeal disease will be excluded; patients with evidence of diffuse subependymal disease or tumor in the brainstem, cerebellum, spinal cord, or cerebrospinal fluid (CSF) will also be excluded\r\n* Patients with radiological evidence of active (growing) multifocal disease, tumors extending into or crossing the corpus callosum or leptomeningeal disease, will be excludedXx_NEWLINE_xXEvidence of ongoing spinal cord compression or leptomeningeal carcinomatosisXx_NEWLINE_xXPatients with leptomeningeal metastasesXx_NEWLINE_xXWidespread definitive leptomeningeal metastasisXx_NEWLINE_xXE 07. History of brain metastases, uncontrolled spinal cord compression, or carcinomatous meningitis or new evidence of brain or leptomeningeal disease.Xx_NEWLINE_xXEvidence of diffuse leptomeningeal disease on brain MRI or by previously documented cerebrospinal fluid (CSF) cytology; NOTE: discrete dural metastases are permittedXx_NEWLINE_xXUncontrolled brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastasesXx_NEWLINE_xXKnown or suspected brain metastasis or active leptomeningeal diseaseXx_NEWLINE_xXKnown or suspected brain metastasis or active leptomeningeal diseaseXx_NEWLINE_xXMultifocal disease or leptomeningeal spreadXx_NEWLINE_xXSymptomatic metastatic brain or leptomeningeal tumors (asymptomatic or treated metastatic brain or leptomeningeal tumors are allowed)Xx_NEWLINE_xXHistory of leptomeningeal carcinomatosisXx_NEWLINE_xXHistory of leptomeningeal carcinomatosisXx_NEWLINE_xXThere is radiographic evidence of leptomeningeal disease prior to study entryXx_NEWLINE_xXSymptomatic CNS involvement (other than signs and symptoms caused by leptomeningeal disease)Xx_NEWLINE_xXPatients with radiographic or cytologic evidence of leptomeningeal or multicentric disease will be excluded and replaced if neededXx_NEWLINE_xXPatients with brain or central nervous system metastases, including leptomeningeal diseaseXx_NEWLINE_xXPatients must have CNS/ leptomeningeal disease including high risk medulloblastoma, or a CNS/leptomeningeal malignancy which is refractory to conventional therapies, or for which no conventional therapy exists, OR a recurrent brain tumors with a predilection for leptomeningeal dissemination (medulloblastoma, primitive neuroectodermal tumor [PNET], rhabdoid tumor)Xx_NEWLINE_xXSymptomatic or untreated leptomeningeal disease or brain metastases or spinal cord compressionXx_NEWLINE_xXSymptomatic CNS metastases or evidence of leptomeningeal disease.Xx_NEWLINE_xXLeptomeningeal disease or any untreated or symptomatic brain metastases, unless the following criteria are met:Xx_NEWLINE_xXLeptomeningeal metastases or spinal cord compression due to disease.Xx_NEWLINE_xXLeptomeningeal disease or carcinomatous meningitisXx_NEWLINE_xXHave symptomatic or uncontrolled brain metastases, spinal cord compression, or leptomeningeal disease requiring concurrent treatmentXx_NEWLINE_xXKnown symptomatic brain mets or leptomeningeal involvementXx_NEWLINE_xXKnown or suspected brain metastasis or leptomeningeal disease.Xx_NEWLINE_xXCNS or leptomeningeal involvement of lymphomaXx_NEWLINE_xXEvidence of leptomeningeal spread of glibolastoma or gliosarcoma.Xx_NEWLINE_xXSymptomatic leptomeningeal, brain metastases, or spinal cord compression.Xx_NEWLINE_xXKnown brain metastases (unless asymptomatic and treated) or leptomeningeal metastases, including suspected leptomeningeal spread with positive cytologyXx_NEWLINE_xXGlioblastoma or gliosarcoma disease with leptomeningeal spreadXx_NEWLINE_xXHistory of or known brain metastases, spinal cord compression, or carcinomatous meningitis, or evidence of brain or leptomeningeal disease on screening computed tomography (CT) scan or MRIXx_NEWLINE_xXUncontrolled brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastasesXx_NEWLINE_xXLeptomeningeal disease as a manifestation of cancerXx_NEWLINE_xXBrain metastases, leptomeningeal disease, uncontrolled seizure disorder, or active neurologic diseaseXx_NEWLINE_xXLeptomeningeal diseaseXx_NEWLINE_xXAny history of leptomeningeal metastasis.Xx_NEWLINE_xXLeptomeningeal disease as a manifestation of cancerXx_NEWLINE_xXBrain or leptomeningeal metastases that are symptomatic and/or requiring treatmentXx_NEWLINE_xXNo known or suspected (associated neurological signs and symptoms) brain metastases (including leptomeningeal involvement)Xx_NEWLINE_xXAny history of leptomeningeal diseaseXx_NEWLINE_xXPatients with brain metastases (treated or untreated) leptomeningeal disease, uncontrolled seizure disorder, or active neurologic diseaseXx_NEWLINE_xXSymptomatic or untreated leptomeningeal or brain metastases or spinal cord compression.Xx_NEWLINE_xXLeptomeningeal diseaseXx_NEWLINE_xXKnown leptomeningeal involvement, brain metastases or spinal cord compression.Xx_NEWLINE_xXKnown brain metastasis or leptomeningeal diseaseXx_NEWLINE_xXHistory of brain metastases, uncontrolled spinal cord compression, or carcinomatous meningitis, or new evidence of brain or leptomeningeal disease.Xx_NEWLINE_xXSubjects with brain metastases, leptomeningeal disease, uncontrolled seizure disorder, or active neurologic diseaseXx_NEWLINE_xXHistory of leptomeningeal disease.Xx_NEWLINE_xXSymptomatic or untreated leptomeningeal diseaseXx_NEWLINE_xXLeptomeningeal diseaseXx_NEWLINE_xXHistory of brain metastases, uncontrolled spinal cord compression, or carcinomatous meningitis or new evidence of brain or leptomeningeal diseaseXx_NEWLINE_xXAssociated with either diffuse subependymal or leptomeningeal dissemination; orXx_NEWLINE_xXLeptomeningeal disease as a manifestation of cancerXx_NEWLINE_xXHistory of leptomeningeal disease or spinal cord compression secondary to metastasis.Xx_NEWLINE_xXAny presence of leptomeningeal disease or any parenchymal brain metastasisXx_NEWLINE_xXMedically apparent CNS lymphoma or leptomeningeal diseaseXx_NEWLINE_xXPresence of leptomeningeal disease or dural metastases.Xx_NEWLINE_xXSubjects with leptomeningeal or brain metastases or spinal cord compression.Xx_NEWLINE_xXLeptomeningeal disease as a manifestation of cancerXx_NEWLINE_xXLeptomeningeal metastasis.Xx_NEWLINE_xXLeptomeningeal diseaseXx_NEWLINE_xXPatients with untreated or uncontrolled brain metastases or leptomeningeal diseaseXx_NEWLINE_xXLeptomeningeal disease as the only manifestation of the current malignancyXx_NEWLINE_xXBrain metastasis, leptomeningeal disease.Xx_NEWLINE_xXUnstable brain or leptomeningeal disease based on history and physical examination.Xx_NEWLINE_xXLeptomeningeal metastases, hemorrhagic metastases, presence of midline shift; please note: leptomeningeal metastases may be allowed if it is limited to cranial metastasis (magnetic resonance imaging [MRI] spine should be completed, within 4 weeks of enrollment, to show that no other leptomeningeal metastases is present) and is not the only metastasis present in the brainXx_NEWLINE_xXSymptomatic uncontrolled brain or leptomeningeal metastasesXx_NEWLINE_xXSymptomatic uncontrolled brain or leptomeningeal metastases.Xx_NEWLINE_xXLeptomeningeal diseaseXx_NEWLINE_xXUncontrolled brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastasesXx_NEWLINE_xXLeptomeningeal disease as the only manifestation of the current malignancyXx_NEWLINE_xXEvidence of CNS or leptomeningeal metastasesXx_NEWLINE_xXEvidence of leptomeningeal spread of disease.Xx_NEWLINE_xXKnown brain metastases not radiographically stable for ?3 months or leptomeningeal diseaseXx_NEWLINE_xXDiagnosis of primary brain tumor; untreated brain metastasis or history of leptomeningeal disease or spinal cord compression;Xx_NEWLINE_xXUntreated brain metastasis or history of leptomeningeal disease or spinal cord compression;Xx_NEWLINE_xXEvidence of leptomeningeal disease by MRI and/or cerebrospinal fluid (CSF) cytologyXx_NEWLINE_xXHas brain metastases, uncontrolled spinal cord compression, or leptomeningeal diseaseXx_NEWLINE_xXThe participant has leptomeningeal disease.Xx_NEWLINE_xXLeptomeningeal disease as the only manifestation of the current malignancyXx_NEWLINE_xXUntreated or symptomatic brain metastasis, leptomeningeal disease or spinal cord compression. Subjects who are on a stable dose of corticosteroids for more than 1 month or off corticosteroids for 2 weeks can be enrolled with approval of medical monitor. Subjects are not permitted to receive enzyme-inducing anti-epileptic drugs.Xx_NEWLINE_xXUncontrolled brain or all leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastasesXx_NEWLINE_xXThe participant has uncontrolled brain or leptomeningeal metastasesXx_NEWLINE_xXPresence of diffuse leptomeningeal disease or gliomatosis cerebri.Xx_NEWLINE_xXHistory of leptomeningeal carcinomatosisXx_NEWLINE_xXHistory of leptomeningeal metastasesXx_NEWLINE_xXLeptomeningeal metastasesXx_NEWLINE_xXUntreated or symptomatic brain metastases or leptomeningeal diseaseXx_NEWLINE_xXLeptomeningeal metastasesXx_NEWLINE_xXKnown or suspected brain metastasis or active leptomeningeal diseaseXx_NEWLINE_xXKnown or suspected brain metastasis or leptomeningeal diseaseXx_NEWLINE_xXHistory of leptomeningeal diseaseXx_NEWLINE_xXActive known or suspected brain metastasis or active leptomeningeal disease needing treatmentXx_NEWLINE_xXActive known or suspected brain metastasis or active leptomeningeal disease undergoing or requiring treatment.Xx_NEWLINE_xXPatients with definitive leptomeningeal metastasesXx_NEWLINE_xXPrevious brain metastases, leptomeningeal disease, or uncontrolled spinal cord compression.Xx_NEWLINE_xXLeptomeningeal diseaseXx_NEWLINE_xXHistory of leptomeningeal carcinomatosisXx_NEWLINE_xXLeptomeningeal metastases; please note: leptomeningeal metastases may be allowed if it is limited to cranial metastasis (MRI spine should be completed, within 4 weeks of enrollment, to show that no other leptomeningeal metastases is present) and is not the only metastasis present in the brainXx_NEWLINE_xXLeptomeningeal diseaseXx_NEWLINE_xXHistory of leptomeningeal metastasesXx_NEWLINE_xXDiffuse leptomeningeal disease at recurrenceXx_NEWLINE_xXHistory of leptomeningeal disease or spinal cord compressionXx_NEWLINE_xXLeptomeningeal diseaseXx_NEWLINE_xXKnown or suspected brain metastasis or active leptomeningeal disease or spinal cord compressionXx_NEWLINE_xXCarcinomatous meningitis or leptomeningeal diseaseXx_NEWLINE_xXSymptomatic, progressive or corticosteroids-requiring documented brain metastases or leptomeningeal disease involvement.Xx_NEWLINE_xXThe participant has symptomatic brain or leptomeningeal metastasis.Xx_NEWLINE_xXThe participant has symptomatic brain or leptomeningeal metastasis.Xx_NEWLINE_xXBrain metastases (even if treated and/or stable), spinal cord compression, carcinomatous meningitis, or leptomeningeal disease.Xx_NEWLINE_xXLeptomeningeal diseaseXx_NEWLINE_xXPatients with primary CNS tumors and leptomeningeal disease are ineligible.Xx_NEWLINE_xX